

Exhibit B

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 4

Complete if Known

Application Number	10/650,365
Filing Date	August 28, 2003
First Named Inventor	Guangwen WEI
Art Unit	1646
Examiner Name	Bruce D. Hissong
Attorney Docket Number	792-A-PCT-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3	Written Opinion of the International Searching Authority for International Application No. PCT/US04/28068, filed August 26, 2004 for HUIYANGTECH (USA) INC., dated March 4, 2004.	
	4	International Search Report for International Application No. PCT/US04/28068, filed August 26, 2004 for HUIYANGTECH (USA) INC., dated March 4, 2005.	
	8	Ivan AMATO, January 22, 2007, "Silent No Longer: Researchers Unearth Another Stratum of Meaning in the Genetic Code," Chemical and Engineering News, 85(4):38-40.	
	9	AUSUBEL et al., Eds., 1999, Chapter Ten, "Analysis of Proteins," from Short Protocols in Molecular Biology, 4th ed., p. 10-1 to 10-8.	
	10	CINATL et al., 2003, "Treatment of SARS with Human Interferons," The Lancet, 362:293-294.	
	11	DAY et al., 1992, "Engineered disulfide bond greatly increases specific activity of recombinant murine interferon-beta," Journal of Interferon Res., 12: 139-143.	
	12	DUAN et al., 2003, "Anti-SARS virus activities of different recombinant human interferons in cell culture system," Chinese J. Clin. Virol., 17(3):205-208.	
	13	HIGGINS et al., 1983, "Intranasal Interferon as Protection Against Experimental Respiratory Coronavirus Infection in Volunteers," Antimicrobial Agents and Chemotherapy, 24(5):713-715.	
	14	HOLLAND, C.C. and T.L. WRIGHT, 1994, "New approaches to treatment of chronic viral hepatitis," Pathology (Phila.), 3(1).	
	15	NACKLEY, A.G. et al., December 22, 2006, "Human Catechol-O-Methyltransferase Haplotypes Modulate Protein Expression by Altering mRNA Secondary Structure," Science, 314:1930-1932.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1460, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3

of

4

Complete if Known

Application Number	10/650,365
Filing Date	August 28, 2003
First Named Inventor	Guangwen WEI
Art Unit	1646
Examiner Name	Bruce D. Hissong
Attorney Docket Number	792-A-PCT-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	16	NASOFF et al., 1999, "High-level expression of human genes in E. coli," Expression, 6(2): 10-11.	
	17	PYRC, K. et al., 2007, "Antiviral strategies against human coronaviruses," Infectious Disorders – Drug Targets, 7:59-66.	
	18	ZHAO, Z. et al., 2003, "Description and clinical treatment of an early outbreak of Severe Acute Respiratory Syndrome (SARS) in Guangzhou, PR China," Journal of Med. Microbiol., 52:715-720.	
	19	U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/927,975 (Atty. Dkt. #796-A-US), Filed August 26, 2004, Dated April 3, 2007.	
	20	U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/928,956 (Atty. Dkt. #792-C-US), Filed August 26, 2004, Dated June 14, 2007.	
	21	U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/928,956 (Atty. Dkt. #792-C-US), Filed August 26, 2004, Dated December 15, 2006.	
	22	Advisory Action Before the Filing of an Appeal Brief for Guangwen WEI, U.S. Serial No. 10/928,474 (Atty. Dkt. #795-A-US), Filed August 26, 2004, Dated May 22, 2007.	
	23	U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/928,474 (Atty. Dkt. #795-A-US), Filed August 26, 2004, Dated August 9, 2007.	
	24	U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/928,474 (Atty. Dkt. #795-A-US), Filed August 26, 2004, Dated February 9, 2007.	
	25	U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/928,474 (Atty. Dkt. #795-A-US), Filed August 26, 2004, Dated August 22, 2006.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/650,365
Filing Date	August 28, 2003
First Named Inventor	Guangwen WEI
Art Unit	1646
Examiner Name	Bruce D. Hissong
Attorney Docket Number	792-A-PCT-US

Sheet 4 of 4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	26	U.S. Office Action for Guangwen WEI, U.S. Serial No. 11/077,813 (Atty. Dkt. #1005-A-US), Filed March 10, 2005, Dated August 1, 2007.	
	27	U.S. Office Action for Guangwen WEI, U.S. Serial No. 11/077,813 (Atty. Dkt. #1005-A-US), Filed March 10, 2005, Dated November 27, 2006.	
	28	U.S. Office Action for Guangwen WEI, U.S. Serial No. 11/077,813 (Atty. Dkt. #1005-A-US), Filed March 10, 2005, Dated August 8, 2006.	
	29	U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/927,975 (Atty. Dkt. #796-A-US), Filed August 26, 2004, Dated September 19, 2007.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.